Mexiletine Shortened QT Interval and Reduced Ventricular Arrhythmias in a Pedigree of Type 2 Long QT Syndrome Combined with Left Ventricular Non-Compaction

Int Heart J. 2021 Mar 30;62(2):427-431. doi: 10.1536/ihj.20-518. Epub 2021 Mar 17.

Abstract

In this study, we present a case of a 22-year-old female with a family history of syncope, suffering from recurrent syncope since childhood. She had an obvious prolonged QTc interval of up to 651 ms, a bifid T wave pattern on electrocardiogram, and torsade de pointes, corresponding to a syncope episode. Additionally, her echocardiogram showed left ventricular non-compaction in the apex. After treatment with mexiletine, the QTc interval has been observed to shorten immediately, and the T wave morphology recovered. A similar effect was also observed in her mother and young sister. Administration of propranolol prolonged her QTc interval. Target sequencing of candidate genes revealed a missense mutation in the pore area of the hERG protein, coded by KCNH2. We diagnosed this as a case of type 2 long QT syndrome in which mexiletine could be effective in shortening the QTc interval.

Keywords: Ion channel; KCNH2; Sudden death; Syncope; Therapy.

Publication types

  • Case Reports

MeSH terms

  • Anti-Arrhythmia Agents / pharmacology
  • Echocardiography
  • Electrocardiography / drug effects*
  • Female
  • Heart Ventricles / diagnostic imaging
  • Heart Ventricles / physiopathology*
  • Humans
  • Long QT Syndrome / drug therapy*
  • Long QT Syndrome / etiology
  • Long QT Syndrome / genetics
  • Mexiletine / pharmacology*
  • Pedigree
  • Tachycardia, Ventricular / complications*
  • Tachycardia, Ventricular / physiopathology
  • Ventricular Function, Left / physiology*
  • Young Adult

Substances

  • Anti-Arrhythmia Agents
  • Mexiletine

Supplementary concepts

  • Long Qt Syndrome 2